New framework aims to modernize atherosclerosis research: full analysis

A newly published review in Atherosclerosis makes the case that atherosclerosis research needs a better bridge between discovery biology and clinical science. Authors Kaloyan Takov, Marie A. C. Depuydt, and Christophe A. T. Stevens argue that despite major advances in lipid-lowering, antithrombotic, antihypertensive, weight-management, and anti-inflammatory therapies, substantial residual risk remains in atherosclerotic cardiovascular disease, pointing to gaps in how the field models disease complexity. Their proposed framework centers on combining human data-rich approaches with innovative experimental models, rather than relying on traditional pipelines alone. (sciencedirect.com)

That argument lands at a time when cardiovascular research is already shifting toward more personalized and mechanistic approaches. Recent commentary in the European Heart Journal points to expanding use of inflammatory and metabolomic biomarkers, polygenic risk scores, and subclinical atherosclerosis measures for risk prediction, while updated ACC/AHA dyslipidemia guidance this year also reflects a broader push toward earlier, more tailored prevention and treatment strategies. In that context, the Atherosclerosis review reads as both a synthesis and a roadmap for how preclinical science may need to evolve to keep pace with clinical expectations. (academic.oup.com)

The review highlights several tools that could help close that translational gap: large-scale datasets, single-cell and other multi-omics technologies, AI-enabled analysis, and polygenic risk scores, alongside experimental systems that better capture vascular biology. It also stresses that in vivo models still matter because they can capture systemic physiology, inter-organ crosstalk, and pharmacokinetic and pharmacodynamic responses that reductionist systems can miss. That complements broader literature on organ-on-a-chip and multiorgan-on-a-chip platforms, which are being positioned as high-fidelity human tissue models with potential to improve mechanistic studies and drug development, but which still face practical challenges around standardization, reproducibility, and integration into development workflows. (sciencedirect.com)

While direct outside reaction to this specific paper was limited in the sources reviewed, the surrounding literature points in the same direction. A recent Nature Reviews Cardiology review describes vasculature-on-a-chip platforms as promising tools to study atherothrombosis and evaluate atheroprotective agents, but notes technical and biological barriers to wider use. Other reviews have similarly argued that patient-specific organ-on-a-chip systems and multiorgan platforms may help validate genetic findings and connect associative signals from genomics or risk scores to functional biology. Inference: the Takov review is part of a broader effort to make cardiovascular research more modular, human-relevant, and decision-oriented, rather than model-centric. (nature.com)

Why it matters: For veterinary professionals, especially those involved in laboratory animal medicine, comparative pathology, translational research, or industry studies, the paper underscores a practical shift in expectations. Animal models are not being sidelined, but they are increasingly being asked to answer narrower, better-defined questions within a larger evidence package that may also include human omics data and engineered tissue systems. That has implications for species selection, endpoint design, biomarker interpretation, and animal welfare strategy. It also raises the bar for showing where a model is informative, and where it is not. (sciencedirect.com)

For veterinary teams, that could translate into more involvement upstream, helping researchers choose the right model for plaque biology, inflammation, thrombosis, or drug safety questions, and more involvement downstream in interpreting how findings may or may not translate to patients. In comparative medicine settings, the message is especially relevant because cardiovascular disease modeling increasingly depends on integrating pathology, imaging, molecular profiling, and systems biology. Reviews of animal-model-based multi-omics research in atherosclerosis already note both the value of these systems and the limitations of commonly used mouse models in recapitulating human disease features consistently. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely focus less on whether novel platforms can replace animal studies, and more on qualification: which combinations of human datasets, chip systems, and in vivo models are robust enough to support target discovery, biomarker development, and therapeutic decision-making. Watch for follow-on papers, consensus statements, and study designs that define those handoffs more explicitly. (sciencedirect.com)